Atossa Therapeutics, Inc.

( )
ATOS After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Other
ARGXargenx SE -2.04%318.080.0%$122.95m
ICLRICON plc 0.69%217.582.8%$118.60m
VRXValeant Pharmaceuticals International, Inc. -1.41%9.7914.1%$57.61m
BGXXBright Green Corp. 18.04%13.280.0%$44.21m
EVOKEvoke Pharma, Inc. 961.67%2.724.2%$36.03m
RVMDRevolution Medicines, Inc. 5.72%16.630.0%$11.19m
AMRNAmarin Corp. Plc -0.70%1.411.5%$9.68m
USNAUSANA Health Sciences, Inc. -1.02%68.634.2%$4.86m
ANIKAnika Therapeutics, Inc. 0.91%21.179.8%$2.24m
ATOSAtossa Therapeutics, Inc. -4.81%0.910.2%$1.53m
NATRNature's Sunshine Products, Inc. 0.42%11.910.4%$1.14m
CLVRClever Leaves Holdings, Inc. -8.48%1.080.0%$0.90m
CDXCChromadex Corp. -5.24%1.812.7%$0.88m
SMFLSmart for Life, Inc. -8.67%0.480.0%$0.64m
IBIOiBio, Inc. -7.14%0.260.2%$0.59m

Company Profile

Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. It offers ForeCYTE and ArgusCYTE diagnostic tests. The ForeCYTE Breast Health Test provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 65. The ArgusCYTE Breast Health Test offers information to help inform about breast cancer treatment options and to help monitor potential recurrence. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.